- Home
- FLUT vs ALNY Comparison
FLUT vs ALNY Comparison
Compare FLUT & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUT
- ALNY
- Stock Information
- Founded
- FLUT 2016
- ALNY 2002
- Country
- FLUT Ireland
- ALNY United States
- Employees
- FLUT N/A
- ALNY N/A
- Industry
- FLUT
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- FLUT
- ALNY Health Care
- Exchange
- FLUT NYSE
- ALNY Nasdaq
- Market Cap
- FLUT 42.3B
- ALNY 34.7B
- IPO Year
- FLUT N/A
- ALNY 2004
- Fundamental
- Price
- FLUT $269.33
- ALNY $249.20
- Analyst Decision
- FLUT Strong Buy
- ALNY Buy
- Analyst Count
- FLUT 13
- ALNY 23
- Target Price
- FLUT $295.75
- ALNY $298.59
- AVG Volume (30 Days)
- FLUT 1.9M
- ALNY 958.7K
- Earning Date
- FLUT 01-01-0001
- ALNY 10-31-2024
- Dividend Yield
- FLUT N/A
- ALNY N/A
- EPS Growth
- FLUT N/A
- ALNY N/A
- EPS
- FLUT N/A
- ALNY N/A
- Revenue
- FLUT $13,569,000,000.00
- ALNY $2,094,795,000.00
- Revenue This Year
- FLUT $21.37
- ALNY $25.14
- Revenue Next Year
- FLUT $15.50
- ALNY $17.13
- P/E Ratio
- FLUT N/A
- ALNY N/A
- Revenue Growth
- FLUT 19.86
- ALNY 21.54
- 52 Week Low
- FLUT $150.65
- ALNY $141.98
- 52 Week High
- FLUT $269.90
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- FLUT 67.99
- ALNY 40.33
- Support Level
- FLUT $260.76
- ALNY $229.86
- Resistance Level
- FLUT $267.26
- ALNY $271.08
- Average True Range (ATR)
- FLUT 5.87
- ALNY 8.92
- MACD
- FLUT 2.41
- ALNY -3.04
- Stochastic Oscillator
- FLUT 85.18
- ALNY 34.94
About FLUT FLUTTER ENTERTAINMENT PLC
In 2016, Irish company Paddy Power merged with UK firm Betfair to form online gaming operator Flutter Entertainment. Today, Flutter has the top digital revenue share in the US, UK and Ireland, Australia, and many other countries. Some of its main brands are FanDuel in the US, Sky Betting & Gaming and Paddy Power in the UK and Ireland, Sportsbet (acquired by Paddy Power in 2009) in Australia, and Sisal in Italy. As of Dec. 31, 2023, the company offered products in over 100 countries and had 12.3 million average monthly users. In 2023, sports betting was 56% of revenue, online gaming 39%, and fantasy sports, horse racing, and other 5%.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.